Results 21 to 30 of about 8,868 (210)

PBK phosphorylates MSL1 to elicit epigenetic modulation of CD276 in nasopharyngeal carcinoma [PDF]

Oncogenesis, 2021
CD276 (also known as B7–H3, an immune checkpoint molecule) is aberrantly overexpressed in many cancers. However, the upregulation mechanism and in particular, whether oncogenic signaling has a role, is unclear.
Meng-Yao Wang, Bin Qi, Fang Wang, Zhi-Rui Lin, Ming-Yi Li, Wen-Jing Yin, Yan-Yi Zhu, Lu He, Yi Yu, Fang Yang, Jin-Quan Liu, Dong-Ping Chen   +11 more
doaj   +3 more sources

COL10A1 promotes tumorigenesis by modulating CD276 in pancreatic adenocarcinoma

BMC Gastroenterology, 2023
Background Pancreatic adenocarcinoma (PAAD) is a lethal malignant tumour. Further study is needed to determine the molecular mechanism and identify novel biomarkers of PAAD. Methods Gene expression data from the GSE62165 microarray were analysed with the
Qiaodong Xu, Jieting Zheng, Zegeng Su, Binlie Chen, Songgang Gu   +4 more
doaj   +3 more sources

Efficacy of the induced pluripotent stem cell derived and engineered CD276-targeted CAR-NK cells against human esophageal squamous cell carcinoma

Frontiers in Immunology
IntroductionChimeric antigen receptor natural killer (CAR-NK) cells have been found to be successful in treating hematologic malignancies and present potential for usage in solid tumors.MethodsIn this study, we created CD276-targeted CAR-expressing NK ...
Xiaolan Lin, Tian Guan, Tian Guan, Yien Xu, Yun Li, Yun Li, Yanchun Lin, Yanchun Lin, Shaobin Chen, Yuping Chen, Xiaolong Wei, Dongsheng Li, Yukun Cui, Yan Lin, Pingnan Sun, Pingnan Sun, Jianmin Guo, Congzhu Li, Jiang Gu, Wei Yang, Haoyu Zeng, Haoyu Zeng, Haoyu Zeng, Changchun Ma, Changchun Ma, Changchun Ma   +25 more
doaj   +2 more sources

CD276 expression enables squamous cell carcinoma stem cells to evade immune surveillance.

Cell Stem Cell, 2021
Immunosurveillance is a critical mechanism guarding against tumor development and progression. Checkpoint inhibitors have shown significant success in cancer treatment, but expression of key factors such as PD-L1 in putative cancer stem cell (CSC ...
Cheng Wang, Yang Li, L. Jia, J. K. Kim, Jiong Li, Peng Deng, Wuchang Zhang, P. Krebsbach, Cun-Yu Wang   +8 more
semanticscholar   +5 more sources

ITGB6 modulates resistance to anti-CD276 therapy in head and neck cancer by promoting PF4+ macrophage infiltration

Nature Communications
Enoblituzumab, an immunotherapeutic agent targeting CD276, shows both safety and efficacy in activating T cells and oligodendrocyte-like cells against various cancers.
Caihua Zhang, Kang Li, Hongzhang Zhu, Maosheng Cheng, Shuang Chen, Rongsong Ling, Cheng Wang, Demeng Chen   +7 more
doaj   +2 more sources

A CD276-Targeted Antibody-Drug Conjugate to Treat Non-Small Lung Cancer (NSCLC)

Cells, 2023
Non-small cell lung cancer (NSCLC) patients, accounting for approximately 85% of lung cancer cases, are usually diagnosed in advanced stages. Traditional surgical resection and radiotherapy have very limited clinical benefits. The objective of this study
Jiashuai Zhang, Zhuoxin (Zora) Zhou, Kai Chen, Seulhee Kim, Irene Soohyun Cho, Tanvi Varadkar, Hailey Baker, Ju Hwan Cho, Lufang Zhou, Xiaoguang (Margaret) Liu   +9 more
doaj   +3 more sources

Engineering CD276/B7-H3-targeted antibody-drug conjugates with enhanced cancer-eradicating capability

Cell Reports, 2023
Summary: CD276/B7-H3 represents a promising target for cancer therapy based on widespread overexpression in both cancer cells and tumor-associated stroma.
Yang Feng, Jaewon Lee, Liping Yang, Mary Beth Hilton, Karen Morris, Steven Seaman, Veera V. Shivaji R. Edupuganti, Kuo-Sheng Hsu, Christopher Dower, Guojun Yu, Daeho So, Pradip Bajgain, Zhongyu Zhu, Dimiter S. Dimitrov, Nimit L. Patel, Christina M. Robinson, Simone Difilippantonio, Marzena Dyba, Amanda Corbel, Falguni Basuli, Rolf E. Swenson, Joseph D. Kalen, Sreedhar Reddy Suthe, Myer Hussain, James S. Italia, Colby A. Souders, Ling Gao, Martin J. Schnermann, Brad St. Croix   +28 more
doaj   +3 more sources

Radiomic features based on pyradiomics predict CD276 expression associated with breast cancer prognosis

Heliyon
Background: CD276 is a promising immune checkpoint molecule with significant therapeutic potential. Several clinical trials are currently investigating CD276-targeted therapies.
Yong Li, Chun-mei Chen, Wei-wen Li, Ming-tao Shao, Yan Dong, Qun-chen Zhang   +5 more
doaj   +3 more sources

Identification of a urinary CD276 fragment for detecting resectable pancreatic cancer using a C-terminal proteomics strategy [PDF]

Scientific Reports
This study aimed to confirm urinary protein fragments in relation to the presence of pancreatic ductal adenocarcinoma (PDAC) via a C-terminal proteomics strategy using exploratory and validation cohorts. Urinary fragments were examined by iTRAQ-labelling
Shuichi Mitsunaga, Nobuaki Okumura, Toshiki Takei, Toshifumi Takao, Hironobu Tsubouchi, Kohei Nakata, Masafumi Nakamura, Yuji Kitahata, Hideki Motobayashi, Masafumi Ikeda, Masamitsu Nakazato   +10 more
doaj   +2 more sources

CD276 Promotes an Inhibitory Tumor Microenvironment in Hepatocellular Carcinoma and is Associated with Poor Prognosis

Journal of Hepatocellular Carcinoma
Wen-Feng Liu,1,2,* Qiu-Yu Jiang,1,2,* Zhuo-Ran Qi,1,2,* Feng Zhang,1,2 Wen-Qing Tang,1,2 Hao-Qi Wang,1,2 Ling Dong1,2 1Department of Gastroenterology and Hepatology, Zhongshan Hospital, Fudan University, Shanghai, People’s Republic of China ...
Liu WF, Jiang QY, Qi ZR, Zhang F, Tang WQ, Wang HQ, Dong L   +6 more
doaj   +2 more sources